1175992-76-3
Chemical Structure
Udenafil-d7
- CAS No.: 1175992-76-3
- Formula:C25H29D7N6O4S
- Molecular Weight:523.70
IUPAC Name: 3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-(2-(1-methylpyrrolidin-2-yl)ethyl)-4-(propoxy-d7)benzenesulfonamide
InChIKey: IYFNEFQTYQPVOC-SHIXOTCGSA-N
SMILES: CCCC1=NN(C)C2=C1NC(C3=C(C=CC(S(NCCC4N(CCC4)C)(=O)=O)=C3)OC([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=NC2=O
Biological Activity: Udenafil-d7 is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Udenafil-d7 | Udenafil-d7 is the deuterium labeled Udenafil. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Udenafil (Standard) | ≥98% | Udenafil (Standard) is the analytical standard of Udenafil. This product is intended for research and analytical applications. Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Udenafil | 99.28% | Udenafil (DA8159) is a potent, selective and orally active phosphodiesterase type 5 (PDE5) inhibitor. Udenafil also inhibits cGMP hydrolysis and can be used for erectile dysfunction research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Paick, J.S., et al., The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med, 2008. 5(4): p. 946-53. [Content Brief]
